-
Je něco špatně v tomto záznamu ?
Fifteen years of single center experience with stem cell transplantation for multiple myeloma: a retrospective analysis
J. Radocha, V. Maisnar, A. Zavrelová, M. Cermanová, M. Lánská, M. Kmonícek, L. Jebavý, M. Bláha, J. Malý, P. Zák
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, práce podpořená grantem
Digitální knihovna NLK
Plný text - Článek
Číslo
Ročník
Zdroj
Zdroj
NLK
Directory of Open Access Journals
od 1997
Free Medical Journals
od 1997
Open Access Digital Library
od 1997-01-01
Medline Complete (EBSCOhost)
od 2012-06-01
ROAD: Directory of Open Access Scholarly Resources
od 1997
- MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- mnohočetný myelom mortalita patologie terapie MeSH
- přežití po terapii bez příznaků nemoci MeSH
- retrospektivní studie MeSH
- senioři MeSH
- transplantace kmenových buněk * MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
INTRODUCTION: Autologous stem cell transplantation (ASCT) became standard of care for patients with multiple myeloma (MM) under the age of 65 years. We routinely perform ASCT for newly diagnosed MM since 1996 in our department. PATIENTS AND METHODS: We retrospectively analyzed all 285 transplants in 185 patients done for MM from January 1996 till December 2010. We analyzed overall survival (OS) and progression-free survival (PFS) regarding conditioning, stage, complete or very good partial remission (CR, VGPR) achievement, renal impairment, single vs. double transplant. RESULTS: Estimated 10-years survival of the whole set of patients is 39% (median survival 95 months). Patients with renal impairment show same OS as those without (p = 0.22). Patients show similar overall survival and event free survival regardless of type of transplant. We observed better outcome in terms of overall survival in patients treated with new drugs (p = 0.0014). Reaching CR or VGPR was not translated into better OS (p = 0.30) and EFS (p = 0.10). Also stage of the disease and whether single or double transplant was used did not make any significant difference in the outcome. CONCLUSION: Stem cell transplantation greatly improved outcome of patients with MM. Poor outcome of allogeneic transplantation in our group of patients is related to high transplant related mortality (20% vs. 0%) and unexpected high relapse rate. There is a trend towards better survival, when new drugs are incorporated at any time in the course of the disease. This fact supports hypothesis that use of these drugs with ASCT should translate into better long-term outcome.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14059438
- 003
- CZ-PrNML
- 005
- 20140606094857.0
- 007
- ta
- 008
- 140526s2013 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14712/18059694.2014.31 $2 doi
- 035 __
- $a (PubMed)23909048
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Radocha, Jakub, $d 1981- $7 xx0233189 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
- 245 10
- $a Fifteen years of single center experience with stem cell transplantation for multiple myeloma: a retrospective analysis / $c J. Radocha, V. Maisnar, A. Zavrelová, M. Cermanová, M. Lánská, M. Kmonícek, L. Jebavý, M. Bláha, J. Malý, P. Zák
- 520 9_
- $a INTRODUCTION: Autologous stem cell transplantation (ASCT) became standard of care for patients with multiple myeloma (MM) under the age of 65 years. We routinely perform ASCT for newly diagnosed MM since 1996 in our department. PATIENTS AND METHODS: We retrospectively analyzed all 285 transplants in 185 patients done for MM from January 1996 till December 2010. We analyzed overall survival (OS) and progression-free survival (PFS) regarding conditioning, stage, complete or very good partial remission (CR, VGPR) achievement, renal impairment, single vs. double transplant. RESULTS: Estimated 10-years survival of the whole set of patients is 39% (median survival 95 months). Patients with renal impairment show same OS as those without (p = 0.22). Patients show similar overall survival and event free survival regardless of type of transplant. We observed better outcome in terms of overall survival in patients treated with new drugs (p = 0.0014). Reaching CR or VGPR was not translated into better OS (p = 0.30) and EFS (p = 0.10). Also stage of the disease and whether single or double transplant was used did not make any significant difference in the outcome. CONCLUSION: Stem cell transplantation greatly improved outcome of patients with MM. Poor outcome of allogeneic transplantation in our group of patients is related to high transplant related mortality (20% vs. 0%) and unexpected high relapse rate. There is a trend towards better survival, when new drugs are incorporated at any time in the course of the disease. This fact supports hypothesis that use of these drugs with ASCT should translate into better long-term outcome.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a přežití po terapii bez příznaků nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mnohočetný myelom $x mortalita $x patologie $x terapie $7 D009101
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a transplantace kmenových buněk $7 D033581
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Maisnar, Vladimír $7 xx0062937 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
- 700 1_
- $a Zavřelová, Alžběta $7 xx0225108 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
- 700 1_
- $a Cermanová, Melanie $7 xx0049345 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
- 700 1_
- $a Lánská, Miriam $7 jx20100315020 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
- 700 1_
- $a Kmoníček, Miloslav $7 xx0156563 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
- 700 1_
- $a Jebavý, Ladislav, $d 1950- $7 mzk2007408362 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
- 700 1_
- $a Bláha, Milan, $d 1938- $7 xx0034440 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
- 700 1_
- $a Malý, Jaroslav, $d 1946- $7 nlk19990073524 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
- 700 1_
- $a Žák, Pavel, $d 1966- $7 mzk2006354145 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
- 773 0_
- $w MED00010947 $t Acta medica (Hradec Králové) / Universitas Carolina, Facultas Medica Hradec Králové $x 1211-4286 $g Roč. 56, č. 1 (2013), s. 9-13
- 856 41
- $u https://actamedica.lfhk.cuni.cz/media/pdf/am_2013056010009.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 3077 $c 1072 $y 4 $z 0
- 990 __
- $a 20140526 $b ABA008
- 991 __
- $a 20140605085451 $b ABA008
- 999 __
- $a ok $b bmc $g 1027795 $s 858067
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 56 $c 1 $d 9-13 $i 1211-4286 $m Acta Medica $n Acta Med. (Hradec Král.) $x MED00010947
- LZP __
- $b NLK118 $a Pubmed-20140526